The results of all 3 of these trials favored the use of SGLT2 inhibitors over placebo, except the difference between study and control was statistically significant in the PRESERVED-HF and EMPEROR-Preserved trials, but non-significant in the EMPERIAL-Preserved trial. This evidence concerns the gene SLC5A2 and hydrops fetalis.